Gilead Sciences, Inc. (GILD) Position Lessened by Gareth Morgan Investments Limited Partnership

Gareth Morgan Investments Limited Partnership trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 52,626 shares of the biopharmaceutical company’s stock after selling 5,159 shares during the quarter. Gareth Morgan Investments Limited Partnership’s holdings in Gilead Sciences were worth $3,725,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of GILD. Pioneer Investment Management Inc. grew its position in Gilead Sciences by 84.0% in the 2nd quarter. Pioneer Investment Management Inc. now owns 3,493,148 shares of the biopharmaceutical company’s stock valued at $247,245,000 after acquiring an additional 1,595,085 shares in the last quarter. Neuberger Berman Group LLC grew its position in Gilead Sciences by 90.9% in the 2nd quarter. Neuberger Berman Group LLC now owns 2,583,196 shares of the biopharmaceutical company’s stock valued at $182,839,000 after acquiring an additional 1,229,916 shares in the last quarter. Harbour Capital Advisors LLC grew its position in Gilead Sciences by 6,595.9% in the 2nd quarter. Harbour Capital Advisors LLC now owns 1,221,804 shares of the biopharmaceutical company’s stock valued at $17,262,000 after acquiring an additional 1,203,557 shares in the last quarter. Principal Financial Group Inc. grew its position in Gilead Sciences by 41.2% in the 2nd quarter. Principal Financial Group Inc. now owns 3,909,105 shares of the biopharmaceutical company’s stock valued at $276,687,000 after acquiring an additional 1,140,112 shares in the last quarter. Finally, Los Angeles Capital Management & Equity Research Inc. grew its position in Gilead Sciences by 75.0% in the 1st quarter. Los Angeles Capital Management & Equity Research Inc. now owns 2,549,292 shares of the biopharmaceutical company’s stock valued at $173,148,000 after acquiring an additional 1,092,206 shares in the last quarter. 74.62% of the stock is owned by hedge funds and other institutional investors.

In other Gilead Sciences news, EVP Gregg H. Alton sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $74.82, for a total transaction of $1,122,300.00. Following the completion of the sale, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 50,000 shares of the company’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the sale, the executive vice president now owns 113,237 shares of the company’s stock, valued at $8,945,723. The disclosure for this sale can be found here. Insiders have sold 446,819 shares of company stock valued at $36,269,486 over the last 90 days. 1.30% of the stock is currently owned by insiders.

GILD has been the subject of several research reports. TheStreet raised Gilead Sciences from a “c+” rating to a “b-” rating in a research report on Thursday, September 7th. Deutsche Bank AG reaffirmed a “buy” rating and issued a $81.00 target price (up from $79.00) on shares of Gilead Sciences in a research report on Thursday, July 27th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $79.00 target price for the company in a research report on Monday, July 17th. Redburn Partners initiated coverage on Gilead Sciences in a research report on Wednesday, July 26th. They issued a “buy” rating for the company. Finally, BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 2nd. One equities research analyst has rated the stock with a sell rating, twelve have given a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $84.87.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.chaffeybreeze.com/2017/11/14/gilead-sciences-inc-gild-position-lessened-by-gareth-morgan-investments-limited-partnership.html.

Gilead Sciences, Inc. (NASDAQ:GILD) opened at $72.85 on Tuesday. The firm has a market capitalization of $96,363.46, a PE ratio of 7.70, a P/E/G ratio of -1.24 and a beta of 1.13. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.56 and a current ratio of 3.68. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm’s revenue was down 13.2% on a year-over-year basis. During the same period in the prior year, the firm posted $2.75 earnings per share. analysts predict that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be paid a dividend of $0.52 per share. The ex-dividend date of this dividend is Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.86%. Gilead Sciences’s dividend payout ratio is presently 23.69%.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply